Standardized SEC financial data for PFIZER INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000078003 · NYSE · Pharmaceutical Preparations.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $41.65B | $81.29B | $101.17B | $59.55B | $63.63B | $62.58B |
| Cost of revenue | $8.48B | $30.82B | $34.34B | $24.95B | $17.85B | $16.07B |
| Gross profit | $33.17B | $50.47B | $66.83B | $34.60B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.82B | $1.98B | $468.0M | $2.92B | $1.11B | $1.20B |
| Inventory | $8.02B | $9.06B | $8.98B | $10.19B | $10.85B | $10.65B |
| Total current assets | $35.07B | $59.69B | $51.26B | $43.33B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $14.40B | $32.92B | $29.27B | $8.70B | $12.74B | $11.70B |
| Capital expenditures | $2.23B | $2.71B | $3.24B | $3.91B | $2.91B | $2.63B |
| Free cash flow | $12.18B | $30.21B | $26.03B | $4.79B |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/PFE/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/PFE/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $45.78B |
| $46.51B |
| R&D expense | $8.71B | $10.36B | $11.43B | $10.68B | $10.82B | $10.44B |
| SG&A expense | $11.60B | $12.70B | $13.68B | $14.77B | $14.73B | $13.79B |
| Interest expense | $1.64B | $1.47B | $1.44B | $2.21B | $3.23B | $2.74B |
| Pretax income | $7.04B | $24.31B | $34.73B | $1.06B | $8.02B | $7.52B |
| Income tax | $370.0M | $1.85B | $3.33B | $1.11B | $28.0M | $266.0M |
| Net income | $9.16B | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B |
| EPS (diluted) | $1.63 | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
Standardized from PFIZER INC's SEC filings — per-share figures split-adjusted. Full history via the API.
| $50.36B |
| $42.90B |
| Property, plant & equipment | $13.74B | $14.88B | $16.27B | $18.94B | $18.39B | $19.32B |
| Goodwill | $49.56B | $49.21B | $51.38B | $67.78B | $68.53B | $71.26B |
| Total assets | $154.23B | $181.48B | $197.21B | $226.50B | $213.40B | $208.16B |
| Total current liabilities | $25.92B | $42.67B | $42.14B | $47.79B | $42.99B | $36.98B |
| Long-term debt | $37.13B | $36.20B | $32.88B | $61.54B | $57.41B | $61.64B |
| Total debt | $39.13B | $37.83B | $35.44B | $63.79B | $61.15B | $64.64B |
| Total liabilities | $90.76B | $104.01B | $101.29B | $137.21B | $124.90B | $121.39B |
| Retained earnings | $90.39B | $103.39B | $125.66B | $118.35B | $116.72B | $114.61B |
| Total equity | $63.47B | $77.46B | $95.92B | $89.29B | $88.50B | $86.78B |
| $9.84B |
| $9.07B |
| Investing cash flow | -$4.27B | -$22.55B | -$15.78B | -$32.28B | $2.65B | -$1.35B |
| Financing cash flow | -$21.64B | -$9.82B | -$14.83B | $26.07B | -$17.14B | -$10.30B |
| Dividends paid | $8.57B | $8.82B | $9.04B | $9.32B | $9.58B | $9.78B |
| Share repurchases | $0 | $0 | $2.00B | $0 | $0 | — |